

Elderly Versus Younger Patients with ANCA-Associated Vasculitis

Maria de los Angeles Gallardo¹, Marina Scolnik¹, Luciano Enrique Pompermayer¹, Valeria Scaglioni² and Enrique R. Soriano³, ¹Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Buenos Aires, Argentina, ²Rheumatology, Hospital Italiano, Buenos Aires, Argentina, ³Internal Medicine, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: ANCA, Elderly and vasculitis

SESSION INFORMATION

Date: Sunday, November 8, 2015

Session Title: Vasculitis Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Clinical characteristics of elderly patients with ANCA-associated vasculitis (AAV) have not been fully elucidated. Advancing age is a risk factor for treatment-related side effects and mortality in AAV patients. Also comorbidities at time of AAV diagnosis have been associated with reduced patients and renal survival. Our objective was to analyze clinical features and outcomes in older patients with AAV compared with younger ones.

Methods: All patients seen at our hospital between years 2000 and 2014 with diagnosis of Granulomatosis with polyangiitis (GPA), Eosinophilic granulomatosis with polyangiitis (EGPA), Microscopic polyangiitis (MPA) and renal-limited ANCA vasculitis (RLV) were included. Patients were divided in an elderly group (age ≥ 65 years) and a younger group (age < 65 years). Clinical features, comorbidities, treatments, renal outcome and mortality were analyzed.

Results: one hundred patients were included (females 70%, mean age at diagnosis 58.4, SD 18.8). Younger patients (n=55) were compared with older ones (n=45) (table 1). Vasculitis renal involvement was significantly more frequent in older patients (p=0.045). No other clinical differences were found between both groups. Hypertension and dyslipidemia were more frequent in patients over 65 years. While relapses were more frequent in the younger group (p=0.02), mortality was increased in the older group (p=0.03). In a logistic regression analysis, chronic renal insufficiency was the only variable associated with mortality (OR 7, CI 1.18-41.7, p=0.032).

Conclusion: elderly patients with AAV had more renal involvement, hypertension and dyslipidemia and increased mortality. Relapses were more frequent in younger patients. Chronic renal insufficiency was independently associated with mortality in the whole group.

Table 1. Comparison between young and elderly patients with ANCA associated vasculitis

	Young ANCA-	Elderly ANCA-	P value
--	-------------	---------------	---------

	associated Vasculitis group (< 65 y) (n=55)	associated Vasculitis group (>= 65 y) (n= 45)	
Females, % (CI)	69% (56.5-81.7)	71.1% (57.3-84.9)	0.83
Age at diagnosis, mean (SD)	45.2 (14.9)	74.6 (6.2)	<0.0001
Type of vasculitis, n (%)	24 (43.6)	14 (31.1)	0.23
- GPA	7 (12.7)	12 (26.7)	0.11
- MPA	10 (18.2)	5 (11.1)	0.35
- EGPA	14 (25.5)	14 (31.1)	0.49
- RLV			
ANCA positivity, n (%)	17 (32.7)	17 (38.6)	0.54
- C ANCA	27 (51.9)	24 (53.3)	0.89
- P ANCA			
Follow-up, years median (IQR)	3.9 (1.7-9.3)	7.6 (3.2-9.4)	0.15
Comorbidities, % (CI 95)	38.2 (25.1-51.3)	71.1 (57.6-84.7)	0.001
- Hypertension	3.6 (1.4-8.7)	11.1 (1.7-20.5)	0.15
- Diabetes	14.5 (5-24)	42.2 (27.4-57)	0.002
- Dyslipidemia	25.9 (14-37.9)	15.6 (4.7-26.4)	0.21
- Ever Smoker			
Initial involvement	56.4 (43-69.8)	75.6 (62.7-88.4)	0.045
- Renal	27.3 (15.2-39.3)	31.1 (17.3-45)	0.67
- Pulmonar infiltrates	10.9 (2.5-19.3)	6.7 (0.8-14.1)	0.46
- Alveolar hemorrhage	18.2 (7.8-28.6)	26.7 (13.4-39.9)	0.31
- Fever	25.5 (13.7-37.2)	40 (25.3-54.7)	0.12
- Constitutional	38 (25-51.3)	22.2 (9.8-34.7)	0.09
- Sinusal	5.5 (0.7-11.6)	4.4 (1.7-10.6)	0.82
- Eye	14.6 (5-24)	11.1 (1.7-20.5)	0.61
- Hearing loss	18.2 (7.8-28.6)	8.9 (0.4-17.4)	0.18

- Arthritis	9.1 (1.3-16.9)	15.6 (4.7-26.4)	0.32
- Cutaneous	14.5 (5-24)	13.3 (3.2-23.5)	0.98
- Mono or polyneuropathy			
Initial treatment, % (CI)	70.9 (58.6-83.2)	73.3 (60.1-86.6)	0.66
- Methylprednisolone IV	10.9 (2.5-19.3)	6.8 (0.8-14.4)	0.48
- Plasmapheresis	76.4 (65-87.8)	81.9 (70.1-93.4)	0.51
- Cyclophosphamide	14.6 (5-24)	15.9 (4.8-27)	0.85
- Dialysis at diagnosis			
Duration of corticosteroids treatment, months, median (IQR)	36 (15-60)	15 (8-30)	0.0006
Major cardiovascular event during follow up, % (CI)	5.5 (0.6-11.6)	13.3 (0.3-23.5)	0.17
Cancer development during follow up, % (CI)	5.5 (0.6-11.6)	4.4 (1.7-10.6)	0.82
Infections requiring hospitalization or IV antibiotics during follow up, % (CI)	20 (9.2-30.8)	31.1 (17.3-45)	0.2
Relapses, % (CI)	36.4 (23.4-49.4)	15.6 (4.7-26.4)	0.02
Renal outcome, % (CI)	30.9 (18.4-43.4)	44.4 (29.6-59.3)	0.16
- Chronic renal insufficiency	9.1 (1.3-16.9)	4.4 (1.7-10.6)	0.37
- End stage renal disease			
Vasculitis Damage Index at the end of follow up, media (SD)	1.3 (1.4)	1.7 (1.4)	0.14
Mortality, % (CI)	6.1 (0.8-13)	22.2 (8.2-36.2)	0.03

Disclosure: M. D. L. A. Gallardo, None; M. Scolnik, None; L. E. Pompermayer, None; V. Scaglioni, None; E. R. Soriano, Abbvie; Janssen; UCB; Roche; Bristol Myers Squibb, 2, Abbvie; UCB; Janssen;

To cite this abstract in AMA style:

Gallardo MDLA, Scolnik M, Pompermayer LE, Scaglioni V, Soriano ER. Elderly Versus Younger Patients with ANCA-Associated Vasculitis [abstract]. *Arthritis Rheumatol*. 2015; 67 (suppl 10). <http://acrabstracts.org/abstract/elderly-versus-younger-patients-with-anca-associated-vasculitis/>. Accessed December 9, 2015.

ACR Meeting Abstracts - <http://acrabstracts.org/abstract/elderly-versus-younger-patients-with-anca-associated-vasculitis/>